MCRB - Seres Therapeutics Inc
IEX Last Trade
0.7976
0.008 0.953%
Share volume: 1,241,987
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.79
0.01
0.96%
Fundamental analysis
25%
Profitability
18%
Dept financing
25%
Liquidity
46%
Performance
27%
Performance
5 Days
-8.05%
1 Month
-36.46%
3 Months
-17.80%
6 Months
-30.38%
1 Year
-77.32%
2 Year
-84.42%
Key data
Stock price
$0.80
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.54 - $3.67
52 WEEK CHANGE
-$0.78
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Eric Shaff
Region: US
Website: http://serestherapeutics.com/
Employees: 486
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://serestherapeutics.com/
Employees: 486
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Recent news